HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today reported solid net income of $3.0 million, or $0.05 per diluted share for the second quarter 2009. The year ago period net income was higher primarily due to the inclusion of $34.5 million in Rx Partner revenue resulting from the licensed sales of generic OxyContin® pursuant to a litigation settlement agreement in 2008 for which there was no comparable amount in 2009. Excluding the second quarter 2008 sales of generic OxyContin®, net income increased $5.3 million to $3.0 million versus a loss of $2.3 million in the prior year period.
